10-Q: Novanta Q3 Profit Plunges Amid Rising Costs, Restructuring

Novanta Inc. reported a significant decline in net income and earnings per share for the third quarter and first nine months of 2025, despite modest revenue growth, driven by increased operating expenses and restructuring costs.

Summary

• Total revenue for the three months ended September 26, 2025, increased by 1.4% to $247.8 million, primarily due to a current year acquisition, partially offset by decreased demand in precision manufacturing and precision medicine products.
• Net income for the three months ended September 26, 2025, decreased by 44.5% to $10.7 million, down from $19.2 million in the prior year period.
• Diluted earnings per common share for the three months ended September 26, 2025, fell to $0.30 from $0.53 in the prior year period.
• For the nine months ended September 26, 2025, total revenue increased by 1.6% to $722.3 million.
• Net income for the nine months ended September 26, 2025, decreased by 23.6% to $36.4 million, down from $47.6 million in the prior year period.
• Diluted earnings per common share for the nine months ended September 26, 2025, decreased to $1.01 from $1.32 in the prior year period.
• Operating income for the three months decreased by 32.9% to $21.8 million, and for the nine months decreased by 17.5% to $69.2 million, mainly due to higher selling, general and administrative (SG&A) expenses and restructuring costs.
• The company acquired Keonn Technologies, S.L. on April 8, 2025, for an estimated total purchase consideration of $75.1 million, which contributed $19.9 million in revenue and $1.0 million in profit before income taxes for the nine months.
• A new $200.0 million share repurchase plan was approved in September 2025, in addition to the remaining $28.4 million under the 2020 plan.
• A new $1.0 billion credit facility was established on June 27, 2025, maturing in June 2030, including a $350.0 million uncommitted accordion feature.

Sentiment

Score: 4

Explanation: While revenue saw modest growth and gross margins improved, the significant decline in net income and EPS, coupled with substantial increases in operating expenses (SG&A, restructuring), indicates a challenging period for profitability. The acquisition and restructuring efforts are contributing to these costs, suggesting short-term headwinds despite strategic long-term moves like the new credit facility and share repurchase plan.

Positives

• Revenue increased modestly for both the three-month (1.4% to $247.8M) and nine-month (1.6% to $722.3M) periods, partly driven by the Keonn acquisition.
• Gross profit increased for both periods, with gross profit margin improving slightly in both Automation Enabling Technologies (47.3% vs 47.1% for Q3) and Medical Solutions (43.0% vs 42.7% for Q3) segments.
• The company secured a new $1.0 billion Senior Credit Facility, extending maturity to June 2030 and including an uncommitted $350.0 million accordion feature, enhancing financial flexibility.
• A new $200.0 million share repurchase plan was approved, signaling confidence in future cash generation and commitment to shareholder returns.
• Net interest expense decreased for both the three-month ($6.0M vs $8.1M) and nine-month ($17.5M vs $24.6M) periods, primarily due to lower average debt levels and a reduced weighted average interest rate (5.32% vs 6.83% for Q3).
• Cash used in investing activities significantly decreased for the nine months ($70.7M vs $206.1M), indicating less capital deployed for acquisitions compared to the prior year.

Negatives

• Net income decreased significantly by 44.5% to $10.7 million for the three months and by 23.6% to $36.4 million for the nine months.
• Diluted EPS decreased by $0.23 to $0.30 for the three months and by $0.31 to $1.01 for the nine months.
• Operating income decreased by 32.9% to $21.8 million for the three months and by 17.5% to $69.2 million for the nine months, primarily due to increased operating expenses.
• Selling, general and administrative (SG&A) expenses increased substantially by 15.9% to $51.4 million for the three months and by 8.6% to $144.1 million for the nine months, driven by ERP system implementation, officer transition costs, and insurance recovery claims.
• Restructuring, acquisition, and related costs surged by 167.2% to $6.7 million for the three months and by 129.3% to $16.8 million for the nine months, largely due to the 2025 restructuring program.
• Cash provided by operating activities decreased significantly to $55.3 million for the nine months, down from $97.0 million in the prior year, mainly due to increased inventory and higher cash paid for income taxes.
• Cash and cash equivalents decreased to $89.2 million as of September 26, 2025, from $114.0 million at December 31, 2024.
• Foreign exchange transaction losses increased to $3.1 million for the nine months, compared to $0.8 million in the prior year, due to U.S. Dollar fluctuations against other currencies and realized losses on foreign currency contracts.

Risks

• Economic and political conditions, including inflation, supply chain disruptions, labor shortages, market volatility, tariffs, and trade restrictions, could adversely affect customer businesses and capital expenditures.
• Dependence on the ability to respond to fluctuations in product demand and continuously innovate to introduce new products in a timely manner.
• Disruptions or breaches in security of IT systems, including those of third-party providers.
• Risks associated with operations in foreign countries and increased use of outsourcing for components manufacturing.
• Exposure to increased tariffs, trade restrictions, or taxes on products.
• Violations of intellectual property rights and the ability to protect intellectual property against infringement.
• Failure to successfully integrate recent and future acquisitions into the business.
• Ability to attract and retain key personnel.
• Product defects or problems integrating products with other vendors' products.
• Disruptions in the supply of certain key components and other goods from suppliers.
• Exposure to extensive medical device regulations, which may impede product approval or result in recalls.
• Potential penalties for violating foreign and U.S. federal and state healthcare laws and regulations.
• Impact of healthcare industry cost containment and healthcare reform measures.
• Changes in governmental regulations related to the business or products.
• Actual or perceived failures to comply with applicable data protection, privacy, and security laws.
• Failure to implement new information technology systems (e.g., ERP) successfully.
• Changes in foreign currency rates.
• Failure to realize the full value of intangible assets.
• Reliance on original equipment manufacturer (OEM) customers and the potential loss of sales from major customers.
• Increasing scrutiny and changing expectations from investors, customers, governments, and other stakeholders regarding corporate sustainability policies.
• Effects of climate change and related regulatory responses.
• Exposure to the credit risk of some customers and in weakened markets.
• Being subject to U.S. federal income taxation even as a non-U.S. corporation.
• Changes in tax laws and fluctuations in effective tax rates, including the impact of the U.S. H.R.1 One Big Beautiful Bill Act and OECD Pillar Two Model Rules.
• Any need for additional capital to adequately respond to business challenges or opportunities and repay or refinance existing indebtedness, which may not be available on acceptable terms or at all.
• Existing indebtedness limiting the ability to engage in certain activities.
• Volatility in the market price for common shares.
• Failure to maintain appropriate internal controls in the future.

Future Outlook

The company expects future operating cash flows to be sufficient to meet operating and capital expenditure needs for at least the next 12 months. It has the ability to expand borrowing capacity by up to $350.0 million through an uncommitted accordion feature in its revolving credit agreement and may seek additional capital (bonds, convertible debt, or equity) for business development or other investing needs. The 2025 restructuring program is anticipated to be substantially completed by the end of 2026, with total charges expected to be approximately $20.0 million. The 2024 restructuring program is also expected to be substantially completed by the end of 2026, with additional charges of $1.5 million to $2.5 million. The company plans to invest $15 million to $20 million in capital expenditures in 2025. Management believes the Purchasing Managers Index (PMI) may indicate the impact of general economic conditions on sales into the advanced industrial market. The company continues to evaluate the implications of the U.S. H.R.1 One Big Beautiful Bill Act on its financial statements.

Management Comments

• Management believes these interim consolidated financial statements include all adjustments and accruals of a normal and recurring nature necessary to fairly state the results of the interim periods presented.
• Management and the company disclaim any obligation to publicly update or revise any forward-looking statements to reflect any changes in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required under applicable law.
• The Chief Executive Officer and Chief Financial Officer concluded that disclosure controls and procedures were effective as of September 26, 2025.

Industry Context

The global economy continues to face significant challenges, including inflation, supply chain disruptions, business slowdowns, labor shortages, and market volatility. New and proposed tariffs by the U.S. Presidential Administration introduce additional uncertainty. While there have been improvements in supply chain on-time deliveries and talent shortages, overall macroeconomic conditions remain uncertain due to geopolitical tensions and trade policy changes. The medical market is influenced by hospital capital spending, surgical procedure growth, regulatory changes, and technology demand, while the advanced industrial market is affected by technology requirements, manufacturing productivity investments, and general economic conditions. Certain advanced industrial sub-segments, like microelectronics and industrial capital equipment, are cyclical.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to various legal proceedings and claims that arise in the ordinary course of business. Management does not believe the outcome of these claims will have a material adverse effect on its consolidated financial statements, but provides no assurance against such an effect.

Related Party Transactions

• No direct or indirect material interest in any related person transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K for Matthew Farrell's appointment.

Stakeholder Impact

• Shareholders: Experienced a significant decrease in EPS, but the approval of a new share repurchase plan could provide future support for share price and return capital.
• Employees: Affected by restructuring programs (2025 and 2024) which include measures to streamline management structures and regionalize manufacturing, potentially leading to job changes or reductions. Keonn employees received equity grants.
• Customers: May benefit from streamlined operations and cost-saving strategies from restructuring, potentially leading to improved service or product offerings. Demand fluctuations in precision manufacturing and precision medicine impacted revenue.
• Creditors: The new $1.0 billion credit facility provides financial stability and extends debt maturity, but increased long-term debt could be a consideration.
• Management: Undergoing officer transition (Matthew Farrell joining Board) and implementing significant restructuring and ERP system changes, indicating a period of high operational focus and change.

Next Steps

• Substantially complete the 2025 restructuring program by the end of 2026, with expected total charges of approximately $20.0 million.
• Substantially complete the 2024 restructuring program by the end of 2026, with expected additional charges of $1.5 million to $2.5 million.
• Utilize the remaining $28.4 million under the 2020 Repurchase Plan for common share repurchases.
• Implement the newly approved 2025 Repurchase Plan for an additional $200.0 million worth of common shares.
• Continue to evaluate the implications of the U.S. H.R.1 One Big Beautiful Bill Act on consolidated financial statements and disclosures.
• Invest approximately $15 million to $20 million in capital expenditures in 2025 for new property, plant and equipment.

Key Dates

Recommendation

While Novanta Inc. achieved modest revenue growth and improved gross margins, the significant decline in net income and EPS, coupled with substantial increases in operating expenses due to restructuring and ERP implementation, presents a mixed financial picture. The strategic acquisition of Keonn and the new credit facility are positive long-term moves, and the new share repurchase plan signals management confidence. However, the short-term profitability challenges and ongoing restructuring costs warrant a cautious approach. A 'hold' recommendation is appropriate as investors should monitor the execution of restructuring plans and the integration of acquisitions to see if these efforts translate into improved profitability in future periods.

Keywords

Novanta Inc., SEC 10-Q, Quarterly Report, Financial Results, Revenue, Net Income, EPS, Operating Income, Keonn Technologies, Acquisition, Restructuring, Share Repurchase, Credit Facility, Automation Enabling Technologies, Medical Solutions, Precision Manufacturing, Robotics and Automation, Advanced Surgery, RFID, OEM, Industrial Automation, Medical Technology, Financial Performance, Corporate Governance, Risk Factors